psoriasis
Conditions
Interventions
Group Secukinumab:Secukinumab
Group Ixekizumab:Ixekizumab
Sponsors
General Hospital of Ningxia Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: ? Patients aged from 18 to 75 years old, both male and female; ?Moderate to severe plaque psoriasis was defined as involving 10% or more of the total surface area at baseline, a physician's global assessment PGA score of 3 or more (on a scale of 0 to 5, 0 indicating no psoriatic lesions and 5 indicating severe psoriasis), and a psoriatic Area and severity score (PASI) of 3 or more (on a scale of 0 to 72, 5 indicating severe psoriasis). The higher the score, the more severe the condition). In addition, patients who have previously received systemic therapy (including biologics) or phototherapy are also eligible; ? Volunteer to participate in this experiment and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1) Severe infection; 2) Allergic to biologics or a history of multiple drug allergies; 3) Patients with active TB infection or untreated latent TB infection indicated by T-spot and chest radiography; 4) Have hepatitis B virus infection or hepatitis B surface antigen positive and have obvious liver function damage; 5) Have a malignant tumor; 6) Recent use of immunosuppressants; 7) A history of substance abuse or mental illness; 8) Patients with severe heart failure; 9) Patients with immune deficiency; 10) Women who are pregnant, breastfeeding, or have a family planning patient in the short term
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| biomarker; | — |
Secondary
| Measure | Time frame |
|---|---|
| treatment effect;Adverse reactions; | — |
Countries
China
Contacts
Public ContactYu Nan
General Hospital of Ningxia Medical University
Outcome results
None listed